Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Completed

SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma

SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma A Prospective Evaluation in Select Patients With Resected Pancreas Cancer

Outcome
Results posted; single-arm, no comparison
Phase
No phase (not a drug trial)
Status
Completed
Study type
Interventional
Start
6 February 2013
Ended
1 June 2018
Enrollment
50 participants
Sites
1
Primary outcomes
Local Progression-free Survival (LPFS) at 1-year; Local Progression-free Survival (LPFS) at 2-years; Local Progression-free Survival (LPFS); Regional Progression-free Survival (RPFS); Regional Progression-free Survival (RPFS) at 2-years
Sponsor type
Academic / other
Results posted
24 November 2021
Last update
24 November 2021

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 24 November 2021
PFS
Local Progression-free Survival (LPFS) at 1-yearStereotactic Body Radiotherapy: 85, n = 43Values: percentage of participantsTime frame: Up to 12 monthsNo analysis posted for this outcome (outcome 1)
PFS
Local Progression-free Survival (LPFS) at 2-yearsStereotactic Body Radiotherapy: 78.12 (57.82 to 93.06), n = 43Values: percentage of participants, 95% Confidence IntervalTime frame: Up to 24 monthsNo analysis posted for this outcome (outcome 2)
PFS
Local Progression-free Survival (LPFS)Stereotactic Body Radiotherapy: NA (41 to NA), n = 49 (Median not determined; upper bound not reached)Values: median percentage of participants, 95% Confidence IntervalTime frame: Up to 24 monthsNo analysis posted for this outcome (outcome 3)
PFS
Regional Progression-free Survival (RPFS)Stereotactic Body Radiotherapy: NA (27 to NA), n = 49 (Median not determined; Upper bound not reached.)Values: months, 95% Confidence IntervalTime frame: Up to 24 monthsNo analysis posted for this outcome (outcome 4)
PFS
Regional Progression-free Survival (RPFS) at 2-yearsStereotactic Body Radiotherapy: 72.2 (57.56 to 87.84), n = 49Values: median percentage of participants, 95% Confidence IntervalTime frame: Up to 24 monthsNo analysis posted for this outcome (outcome 5)
Primary outcome
Distant Metastasis-free Survival (DMFS) at 2 YearsStereotactic Body Radiotherapy: 49.69 (31.98 to 67.43), n = 49Values: percentage of participants, 95% Confidence IntervalTime frame: Up to 24 monthsNo analysis posted for this outcome (outcome 6)
Primary outcome
Distant Metastasis-free Survival (DMFS)Stereotactic Body Radiotherapy: 21 (12 to NA), n = 49 (Upper bound not reached.)Values: median percentage of participants, 95% Confidence IntervalTime frame: Up to 24 monthsNo analysis posted for this outcome (outcome 7)
Participants
Stereotactic Body Radiotherapy: 50 started, 49 completed
Serious adverse events
Stereotactic Body Radiotherapy: 0 of 49Participants with at least one serious adverse event, of those at risk, as posted
8 secondary outcomes
Acute Toxicities Associated With SBRT
Stereotactic Body Radiotherapy 4.1, n=49 [percentage of participants]
Late Toxicities Associated With SBRT
Stereotactic Body Radiotherapy 0, n=49 [percentage of participants]
PFS · 2-year Progression-free Survival (PFS)
Stereotactic Body Radiotherapy 32.79 (17.49 to 50.25), n=49 [median percentage of participants, 95% Confidence Interval]
Time to Progression (TTP)
Stereotactic Body Radiotherapy 12 (7 to 27), n=49 [median months, 95% Confidence Interval]
OS · Overall Survival (OS)
Stereotactic Body Radiotherapy 18 (13 to 20), n=50 [median months, 95% Confidence Interval]
OS · Overall Survival (OS) at 1-year
Stereotactic Body Radiotherapy 68, n=50 [percentage of participants]
OS · Overall Survival (OS) at 2-years
Stereotactic Body Radiotherapy 39.95 (24.44 to 56.68), n=50 [percentage of participants, 95% Confidence Interval]
Quality of Life (QoL) FACT-G
Physical well-being (PWB) - Before treatment (bas…: Stereotactic Body Radiotherapy 24 (12 to 27), n=22 [median score on a scale, Inter-Quartile Range] (first of 25 rows)

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The current study seeks to further investigate the impact of Stereotactic Body Radiation Therapy following pancreatic resection with a close or positive margin. The investigators hope to improve local control, and through the use of a shortened treatment schedule, allow patients to begin systemic therapy earlier.

Detailed description public domain (ClinicalTrials.gov)

Radiation simulation will be done in Shadyside Radiation Oncology department Contrast-enhanced CT based simulation will be obtained prior to any adjuvant treatment (2-4 weeks post-op depending on healing). The target volume will be identified based on fiducial marker placement at time of surgery as well as a detailed discussion and image review with the operating surgeon. This are will be contoured on axial CT images obtained at 1.25 mm slice thickness. These volumes will then be reconstructed into a 3-dimensional image set for SBRT planning. Subjects will be simulated in the treatment position (supine with arms raised) on the CT scanner table the appropriate immobilization. Optiray® contrast will be administered intravenously at a flow rate of 2.5 mL/s. A helical CT scan of the abdomen will be acquired with intravenous contrast starting 30 seconds prior to CT acquisition. A 4D CT data acquisition for the same axial extent will be obtained. The images will then be electronically transferred from the CT workstation via DICOM3 to the appropriate treatment planning workstation in the department of radiation oncology. Based on axial CT images, fiducial marker placement, review of the pathology report, and a detailed discussion with the operating surgeon, contours will be drawn of the clinical target volume (CTV), which is defined as the area at risk for microscopic disease. The planning target volume (PTV) will be equivalent to the CTV unless motion is detected on the 4D motion study. If there is motion, the amount of motion in the superior-inferior, lateral, and anterior-posterior directions will be the margin given. Surrounding normal and critical structures will also be contoured by the treating radiation oncologist including the kidneys, liver, small bowel, spinal cord, and stomach if necessary. Stereotactic Body Radiotherapy Planning An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV. Careful evaluation of each plan will be conducted by the radiosurgical team to ensure that normal tissues and critical structures tolerances are maintained. The maximum dose (in Gy) within the treatment volume (MD), prescriptions dose (PD), and the ratio of MD/PD (as a measure of heterogeneity within the target volume), prescription isodose volume (PIV in mm3), tumor volume (TV in mm3), and the ratio of PIV/TV (as a measure of dose conformity of the treatment relative to the target) will be recorded. Evaluation during treatment The subjects will be carefully followed while on active treatment and post-treatment for 24 months, or until death. Treatment following SBRT All patients will have been seen in a multi-disciplinary pancreatic cancer clinic. As such, they will be set up with a medical oncologist. Following completion of SBRT as described in this protocol, the patient's medical oncologist may, at his/her discretion, administer systemic therapy according to the current standard of care or the UPMC pathways.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Local Progression-free Survival (LPFS) at 1-year [Up to 12 months]. Number, percentage of participants. Stereotactic Body Radiotherapy (n=43): 85.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Local Progression-free Survival (LPFS) at 2-years [Up to 24 months]. Number, percentage of participants (95% Confidence Interval). Stereotactic Body Radiotherapy (n=43): 78.12 (57.82 to 93.06).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Local Progression-free Survival (LPFS) [Up to 24 months]. Median, percentage of participants (95% Confidence Interval). Stereotactic Body Radiotherapy (n=49): NA (41 to NA) [Median not determined; upper bound not reached].

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Regional Progression-free Survival (RPFS) [Up to 24 months]. Number, months (95% Confidence Interval). Stereotactic Body Radiotherapy (n=49): NA (27 to NA) [Median not determined; Upper bound not reached.].

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Regional Progression-free Survival (RPFS) at 2-years [Up to 24 months]. Median, percentage of participants (95% Confidence Interval). Stereotactic Body Radiotherapy (n=49): 72.2 (57.56 to 87.84).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Distant Metastasis-free Survival (DMFS) at 2 Years [Up to 24 months]. Number, percentage of participants (95% Confidence Interval). Stereotactic Body Radiotherapy (n=49): 49.69 (31.98 to 67.43).

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Distant Metastasis-free Survival (DMFS) [Up to 24 months]. Median, percentage of participants (95% Confidence Interval). Stereotactic Body Radiotherapy (n=49): 21 (12 to NA) [Upper bound not reached.].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Acute Toxicities Associated With SBRT [Up to 24 months]. Number, percentage of participants. Stereotactic Body Radiotherapy (n=49): 4.1.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Late Toxicities Associated With SBRT [Up to 24 months]. Number, percentage of participants. Stereotactic Body Radiotherapy (n=49): 0.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

2-year Progression-free Survival (PFS) [Up to 24 months]. Median, percentage of participants (95% Confidence Interval). Stereotactic Body Radiotherapy (n=49): 32.79 (17.49 to 50.25).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Time to Progression (TTP) [Up to 24 months]. Median, months (95% Confidence Interval). Stereotactic Body Radiotherapy (n=49): 12 (7 to 27).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) [Up to 24 months]. Median, months (95% Confidence Interval). Stereotactic Body Radiotherapy (n=50): 18 (13 to 20).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) at 1-year [Up to 12 months]. Number, percentage of participants. Stereotactic Body Radiotherapy (n=50): 68.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) at 2-years [Up to 12 months]. Number, percentage of participants (95% Confidence Interval). Stereotactic Body Radiotherapy (n=50): 39.95 (24.44 to 56.68).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Quality of Life (QoL) FACT-G [Up to 24 months (before treatment (baseline), shortly after neo-adjuvant treatment, shortly after surgery, shortly after SBRT, shortly after Adjuvant treatment)]. Median, score on a scale (Inter-Quartile Range). Physical well-being (PWB) - Before treatment (baseline): Stereotactic Body Radiotherapy (n=22): 24 (12 to 27). Physical well-being (PWB) - Shortly after neo-adjuvant treatment: Stereotactic Body Radiotherapy (n=22): 25 (23 to 27). Physical well-being (PWB) - Shortly after surgery: Stereotactic Body Radiotherapy (n=22): 24 (21 to 25). Physical well-being (PWB) - Shortly after SBRT: Stereotactic Body Radiotherapy (n=22): 23 (15 to 27). Physical well-being (PWB) - Shortly after adjuvant treatment: Stereotactic Body Radiotherapy (n=22): 18 (9 to 26). Social/family well-being (SWB) - Before treatment (baseline): Stereotactic Body Radiotherapy (n=22): 26 (19 to 28). Social/family well-being (SWB) - Shortly after neo-adjuvant treatment: Stereotactic Body Radiotherapy (n=22): 28 (28 to 28). Social/family well-being (SWB) - Shortly after surgery: Stereotactic Body Radiotherapy (n=22): 25 (23 to 28). Social/family well-being (SWB) - Shortly after SBRT: Stereotactic Body Radiotherapy (n=22): 26 (20 to 28). Social/family well-being (SWB) - Shortly after adjuvant treatment: Stereotactic Body Radiotherapy (n=22): 17 (15 to 18). Emotional well-being (EWB) - Before treatment (baseline): Stereotactic Body Radiotherapy (n=22): 17 (16 to 19). Emotional well-being (EWB) - Shortly after neo-adjuvant: Stereotactic Body Radiotherapy (n=22): 22 (20 to 23). Emotional well-being (EWB) -Shortly after surgery: Stereotactic Body Radiotherapy (n=22): 20 (16 to 22). Emotional well-being (EWB) -Shortly after SBRT: Stereotactic Body Radiotherapy (n=22): 21 (17 to 22). Emotional well-being (EWB) - Shortly after adjuvant treatment: Stereotactic Body Radiotherapy (n=22): 14 (12 to 16). Functional well-being (FWB) - Before treatment (baseline): Stereotactic Body Radiotherapy (n=22): 14 (5 to 23). Functional well-being (FWB) - Shortly after neo-adjuvant: Stereotactic Body Radiotherapy (n=22): 20 (11 to 28). Functional well-being -Shortly after surgery: Stereotactic Body Radiotherapy (n=22): 22 (14 to 27). Functional well-being (FWB) Shortly after SBRT: Stereotactic Body Radiotherapy (n=22): 13 (11 to 21). Functional well-being (FWB) Shortly after adjuvant treatment: Stereotactic Body Radiotherapy (n=22): 17 (13 to 20). Total score - Before treatment (baseline): Stereotactic Body Radiotherapy (n=22): 83 (52 to 95). Total score - Shortly after neo-adjuvant: Stereotactic Body Radiotherapy (n=22): 94 (82 to 106). Total score - Shortly after surgery: Stereotactic Body Radiotherapy (n=22): 85 (77 to 94). Total score - Shortly after SBRT: Stereotactic Body Radiotherapy (n=22): 78 (73 to 89). Total score - Shortly after adjuvant treatment: Stereotactic Body Radiotherapy (n=22): 64 (53 to 76).